The Expedition 3 Study
This phase 3, placebo-controlled, double-blind, parallel-group, bayesian adaptive randomized design and dose regimen-finding study to evaluate safety, tolerability and efficacy of Solanezumab in subjects with early Alzheimer’s disease.
The study drug is called Solanezumab, a humanized monoclonal antibody that targets amyloid beta.
What happens during the study?
A telephone screening will be conducted to determine if you are eligible to come in for an in-person screening visit. This screening visit to determine if you are eligible for the study. As part of the screening procedures, you will have a MRI and a PET scan using Amyvid, an FDA-approved compound to determine the presence or absence of amyloid deposits in the brain.
Patients enrolled in the study receive either the study drug, Solanezumab, or placebo intravenously every four weeks for a period of 18 months.
They will have tests of memory to assess the effects of the study drug, along with MRIs, physical examinations and EKGs to assess for drug safety.
Where is this study taking place?
Meet the team
Robert A. Stern, PhD – Principal Investigator
Wendy Qiu, MD, PhD – Study Physician
Jesse Mez, MD – Study Physician
Jane Mwicigi, MPH – Study Coordinator
Diane Essis – Recruitment Coordinator
Meenakshi Chivukula – Research Assistant
Please call 617-414-1077 or email JoinADC@bu.edu for more information and to participate.
Sponsor – Eli Lilly and Co.